

May 17, 2007

TENURE RECOMMENDATION  
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL  
DEPARTMENT OF INTERNAL MEDICINE

Vallerie V. McLaughlin, M.D., is recommended for the granting of tenure to be held with her title of Associate Professor of Internal Medicine, Department of Internal Medicine, Medical School.

Academic Degrees:

M.D.	1989	Northwestern University
B.S.	1985	Northwestern University

Professional Record:

2003-Present	Associate Professor of Internal Medicine, University of Michigan
2002-2003	Associate Professor of Medicine, Rush Medical College
1996-2002	Assistant Professor of Medicine, Rush Medical College
1995-1996	Instructor in Medicine, University of Illinois at Chicago

Summary of Evaluation:

Teaching: Dr. McLaughlin teaches students, house officers, and fellows on a daily basis. Attending on the inpatient service 10-12 weeks per year, Dr. McLaughlin often works with 2-3 students, 2 interns and 1 resident. Dr. McLaughlin also teaches students, house officers, and fellows when they care for her pulmonary hypertension patients at times other than when she is on service. Dr. McLaughlin frequently has a third-year medical student in her outpatient clinic. Both pulmonary fellows and pediatric cardiology fellows, by request, have rotated in Dr. McLaughlin's outpatient pulmonary hypertension clinic as it provides an excellent educational opportunity for them. Dr. McLaughlin gives a resident conference on pulmonary hypertension on a yearly basis, and gives 2-3 morning reports annually. Dr. McLaughlin speaks at CME events locally and nationally on a regular basis. Dr. McLaughlin has given the lecture on pulmonary hypertension at the American College of Cardiology Board Review course for nine consecutive years. Dr. McLaughlin is Chair of the Pulmonary Hypertension Association Medical Education Sessions, a series taking place in six U.S. cities this fall. Dr. McLaughlin has mentored two University of Michigan residents on research projects since her arrival three years ago. Both of these residents presented their research at American Thoracic Society meetings. Comments from her trainees indicate that she is a superb educator.

Research: Dr. McLaughlin's main research focus has been in the area of therapies for pulmonary arterial hypertension. Under her leadership, the University's pulmonary hypertension program has been a leading enroller in many randomized, controlled trials (RCTs). She has served on the steering committee of three RCTs and is currently Chair of the steering committee of the COMPASS-2 trial, the first ever morbidity and mortality trial in pulmonary hypertension. Dr. McLaughlin has authored many papers on the effects of various therapies in pulmonary

hypertension. She is the principal investigator of the Pulmonary Hypertension Breakthrough Initiative Data Coordinating Center and the Chair of the Steering Committee for the Pulmonary Hypertension Breakthrough Initiative. In this role, she coordinates data and research for about a dozen centers across the country.

Recent and Significant Publications:

McLaughlin VV, Oudiz RJ, Adaani F, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Car Med* [In press].

McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Rainisio M, Simmoneau G, Rubin LJ: Survival and safety of first-line bosentan therapy in patients with primary pulmonary hypertension. *Eur Respiratory J* 25(2):244-249, 2005.

Badesch DB, Abman SN, Ahearn G, Barst RJ, McCrory D, Simmoneau G, McLaughlin V: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based guidelines for clinical practice. *Chest* 126:35S-77S, 2004.

McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahern G: Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest* 126:78S-92S, 2004.

McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. *Circ* 106:1477-1482, 2002.

Professional Work: Dr. McLaughlin directs the Pulmonary Hypertension Program at the University of Michigan, which has become one of the leading centers for pulmonary hypertension in the country. Dr. McLaughlin and her team provide highly specialized care to this very ill population of patients with a rare, in fact, orphan, disease. Given the association of pulmonary hypertension with certain other disorders, Dr. McLaughlin commonly interacts with other services including pulmonary and critical care, hepatology, and rheumatology.

Service: New referrals to the pulmonary hypertension program have more than tripled since Dr. McLaughlin joined the faculty in 2003. This is due to the extensive outreach program that she has developed. She has promoted the University of Michigan Pulmonary Hypertension Program by giving lectures at hospitals and to practices around the state. Dr. McLaughlin brings prestige to the University by her involvement in numerous organizations, commonly in leadership positions. Dr. McLaughlin has recently completed a two-year term as Chair of the AHA Women in Cardiology Committee. She currently serves on the ACC Program Committee. Dr. McLaughlin serves on the American College of Chest Physicians Pulmonary Arterial Hypertension Guidelines Panel and currently is the Chair of the AHA/ACC Clinical Expert Consensus Document. She is the editor in chief of *Advances in Pulmonary Hypertension*, the official journal of the Pulmonary Hypertension Association. She is the Vice-Chair of the Pulmonary Hypertension Scientific Leadership Council.

External Review:

Reviewer A: “She has emerged as one of the leading authorities on pulmonary hypertension and has authored...many of the most definitive papers in this field...She is an articulate, thoughtful and provocative speaker and an enthusiastic educator...Dr. McLaughlin is an innovative and highly motivated clinical investigator who has achieved national and international recognition.”

Reviewer B: “Simply stated, Dr. McLaughlin, throughout her career, has been a shining example of interdisciplinary and educational collaboration in the field of academic pulmonary hypertension.”

Reviewer C: “She is an exemplary academic physician acting as a role model, teacher and researcher...Dr. McLaughlin is a leader in the field, and is at the front of her peer group...She deserves tenure, and if she was at my institution, I would do my utmost to hold on to her. Her career and retention should be encouraged.”

Reviewer D: “...I enthusiastically support Dr. McLaughlin’s promotion to a tenure level associate professor because of her accomplishments as an academic investigator with expertise in the clinical management of patients with pulmonary hypertension. I am positive that in this capacity, Dr. McLaughlin will be successful and will continue contributing significantly to the field.”

Reviewer E: “...Valerie has shown an energy and ambition that continues to be rewarded with more and more responsibility and productivity. She has risen to the top echelon in the PAH community both nationally and internationally, and she will certainly work at that level for the rest of her career.”

Reviewer F: “Her studies are highly cited and have shaped the way we approach the treatment of pulmonary hypertension.”


Reviewer G: “...Dr. McLaughlin is a star in her field, has great national recognition and brings great credit to the University of Michigan Medical School.”

Reviewer H: “Her research to date is superb and her skills as an educator are excellent...She is a national and international figure in pulmonary hypertension and is one of the top 10 clinical pulmonary hypertension researchers in the world.”

Reviewer I: “Her scientific rigor and intellectual integrity are especially appreciated. Valerie is one of the worldwide clinician leader[s] in the PAH field as illustrated by the quality of her papers.”

Summary of Recommendation:

Dr. McLaughlin is an acknowledged expert in the treatment of patients with pulmonary hypertension. She has led and is leading major national trials in this area, most recently one in which combination vasodilatory and vascular remodeling therapies are used. I recommend her for the granting of tenure in the Department of Internal Medicine with the highest level of enthusiasm.

A handwritten signature in black ink, appearing to read 'J.O. Woolliscroft', written over a horizontal line.

James O. Woolliscroft, M.D.  
Interim Dean  
*Lyle C. Roll Professor of Medicine*

May 2007